Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
261 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Exclude Unknown | Expanded Access Studies (261 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Approved for marketing Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device
Condition: Arthroplasty of the MCP Joint
Intervention: Device: SR™MCP
2 Available Islet Transplant for Type 1 or Surgical Diabetes
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia;   Labile Diabetes;   End-stage Renal Disease
Intervention: Biological: Allogeneic islets of Langerhans
3 Available Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
Conditions: Pancreas;   Cancer;   Locally Advanced Pancreatic Cancer;   Non-invasive Treatment
Intervention: Procedure: Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)
4 No longer available LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBW 2992
5 Available Compassionate Use of the Incraft® AAA Stent Graft System
Condition: Abdominal Aortic Aneurysm
Intervention: Device: Endovascular AAA repair
6 Approved for marketing A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib (GDC-0449)
7 Available Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: suspension of erythrocytes encapsulating L-asparaginase
8 Temporarily not available Development of a Fall Prevention and Fall Detection System for Ambulatory Rehabilitation of Parkinson's Patients
Condition: Parkinson's Disease
Intervention: Other: portable motion detector
9 No longer available Single Patient Expanded Access Protocol: Metabolic Boost
Condition: Metachromatic Leukodystrophy
Intervention: Biological: Enriched Hematopoetic Stem Cell Transplant
10 No longer available Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
Condition: Melanoma
Intervention: Drug: Ipilimumab
11 No longer available Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
Condition: Byler Disease
Intervention: Drug: Glycerol phenylbutyrate
12 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Conditions: GBM;   Glioblastoma Multiforme
Intervention: Biological: DCVax-L
13 Available EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
14 Available An Extended Access Program for Perampanel
Condition: Partial Onset Seizures
Intervention: Drug: Perampanel
15 Available 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS);   Congenital Myasthenia (CM)
Intervention: Drug: 3,4-diaminopyridine
16 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
17 Available Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 DAP
18 Available Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
Conditions: Cholestasis;   Short Bowel Syndrome
Intervention: Drug: Omegaven
19 No longer available B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
Condition: Type 1 Diabetes Mellitus
Interventions: Biological: Allogeneic Pancreatic Islet Cells;   Drug: Sirolimus;   Biological: Basiliximab;   Drug: Tacrolimus;   Drug: Antibacterial, Antifungal, and Antiviral Prophylaxis;   Drug: Trimethoprim/sulfamethoxazole;   Drug: Clotrimazole;   Drug: Valganciclovir;   Drug: Heparin;   Drug: Enoxaparin;   Drug: Pentoxifylline;   Drug: Aspirin
20 Available TX2® Low Profile Endovascular Graft
Conditions: Aortic Aneurysm;   Penetrating Ulcer;   Vascular Disease
Intervention: Device: TX2® Low Profile TAA Endovascular Graft

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years